scholarly journals The risk of development of prostatic hyperplasia and prostate cancer in patients presenting with acromegalia

2010 ◽  
Vol 56 (5) ◽  
pp. 30-32
Author(s):  
R V Rozhivanov ◽  
A A Fabrichnova ◽  
A E Lepetukhin ◽  
S A Dubskiĭ ◽  
D G Kurbatov
Keyword(s):  
Prostate Cancer ◽  
General Population ◽  
Prostate Gland ◽  
Age Groups ◽  
Prostatic Hyperplasia ◽  
Present Review ◽  
Prostatic Diseases

The objective of the present review was to consider the available data on the risk of development of prostatic hyperplasia and prostate cancer in patients presenting with acromegalia. It is shown that the incidence of prostatic diseases in acromegalic patients is significantly higher than in the general population. Prostatic hyperplasia occurs in patients of all age groups presenting with acromegalia while its treatment reduces the volume of the prostate gland. The reviewed publications do not report cases of prostate cancer.

scholarly journals The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective

Medicines ◽  
2021 ◽  
Vol 8 (6) ◽  
pp. 30
Author(s):  
Teow J. Phua
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cell Biology ◽  
Cancer Biology ◽  
Cost Savings ◽  
Prostatic Hyperplasia ◽  
Biological Processes ◽  
New Perspective ◽  
Prostatic Diseases

Background: The etiology of benign prostatic hyperplasia and prostate cancer are unknown, with ageing being the greatness risk factor. Methods: This new perspective evaluates the available interdisciplinary evidence regarding prostate ageing in terms of the cell biology of regulation and homeostasis, which could explain the timeline of evolutionary cancer biology as degenerative, inflammatory and neoplasm progressions in these multifactorial and heterogeneous prostatic diseases. Results: This prostate ageing degeneration hypothesis encompasses the testosterone-vascular-inflamm-ageing triad, along with the cell biology regulation of amyloidosis and autophagy within an evolutionary tumorigenesis microenvironment. Conclusions: An understanding of these biological processes of prostate ageing can provide potential strategies for early prevention and could contribute to maintaining quality of life for the ageing individual along with substantial medical cost savings.

scholarly journals PREPARASI PEREAKSI KIT IMMUNORADIOMETRlCASSAY FREE PROSTATE SPECIFIC ANTIGEN UNTUK DETEKSI KANKER PROSTAT

2013 ◽  
Vol 15 (2) ◽  
pp. 14-24
Author(s):  
Puji Widayati ◽  
Gina Mondrida ◽  
Sri Setiyowati ◽  
Agus Ariyanto ◽  
V. Yulianti Susilo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Free Condition ◽  
Free Psa ◽  
Prostate Enlargement ◽  
Assay Design ◽  
Benign Prostate

Prostate Specific Antigen (PSA) is a glycoprotein with a molecular weight of approximately 34,000 daltons serine protease secreted exclusively by prostatic epithelial cells that lining acini and prostate gland. Increased of PSA levels can be caused by prostate cancer or benign prostate enlargement (benign prostatic hyperplasia, BPH). PSA in the blood was found in the free condition (free PSA) and most of the bound protein (complexed-PSA, c-PSA). Measuring levels of PSA was found in the blood can be done by several methods such as by immunoradiometricassay (IRMA) methods or ELISA methods. IRMA method is one of immunoassay techniques using radionuclides ,/' 125 oJ I as a tracer, so the sample in small 13 quantity can be detected The purpose of this study was obtained PSA reagent kit that includes 1251labeled PSA as a tracer, PSA coated tube and PSA standard that requirements of the kit, then it can be optimized assay design, that eventually PSA reagent kit can be used for early detection of prostate cancer. It has been done labeling of Mab PSA using 125 1with reaction time was 90 seconds, amount of PSA MAb was 75 ugram and the activity of Na_ 125I was 1000 flCi. Preaparation of PSA coated tube using 0.05 M Na2C03 solution, at pH: 9.6 with volume was 250 ml., standard PSA with 0.025 Mphosphate buffer at pH 7.4 containing 5% BSA and 0.1% NaN3, and resulting at 1,25% and 14,12% respectively of NSB and BIT that requirement of the kit.Keywords: Prostate cancer, PSA, IRMA,NSB, Maximum Binding

scholarly journals A Review on Serenoa serrulata: A Potential Medicinal Plant for Prostatic Diseases

2021 ◽  
Vol 3 (1) ◽  
pp. 19-33
Author(s):  
Jacqueline Aber ◽  
Bruhan Kaggwa ◽  
Hedmon Okella ◽  
Clement Olusoji Ajayi ◽  
Patrick Engeu Ogwang
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Adverse Effects ◽  
Medicinal Plant ◽  
Cucurbita Pepo ◽  
Prostatic Hyperplasia ◽  
Research Articles ◽  
Echinacea Angustifolia ◽  
Saw Palmetto ◽  
Prostatic Diseases

Background: Prostatic diseases which include prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer are the benign or malignant disorders that affect the prostate. Phytotherapies have been adopted as the alternative treatment/ management option especially for BPH since the current modern methods of treatment presents a lot of adverse effects. Methodology: The literature was searched using different databases including Medline/PubMed, Cochrane library, Scopus, Proquest library, Embase, EBooks and Google Scholar for relevant records for a period from 1988 to 2018 to identify all the published articles of S. serrulata regarding treatment of prostatic diseases. The key search terms were Serenoa serrulata, S. repens, Saw palmetto, Prostate cancer treatment with Serenoa serrulata, treatment of Benign Prostatic Hyperplasia with Serenoa serrulata,  phytochemicals of Serenoa serrulata, ethnobotanical uses of Serenoa serrulata, toxicity of Serenoa serrulata, pharmacological activities of Serenoa serrulata and also traditional management and treatment of prostatic diseases  using Serenoa serrulata and also clinical trials on treatment of prostatic diseases  with Serenoa serrulata. The retrieved articles were reviewed, synthesized and analyzed qualitatively. The reference list of the retrieved articles was also reviewed and synthesized. The original research articles which reported an investigation of S. serrulata of any study design, original published research articles, any time of publication and grey literature (conference papers, reported articles, academic thesis) were included. The articles whose full texts were not freely available by the time of search and those without clear information about methodology and study design were excluded. Results: This review reported that Serenoa serrulata belonging to the Arecaceae family commonly known as saw palmetto is used traditionally for treating prostatic disease conditions and other infertility conditions in both men and women. Phytochemical screening of hexanic and ethanolic extracts of S. serrulata comprised of free fatty acids and phytosterols which together contribute to their antiprostatic activities. These extracts of S. serrulata exhibited antiandrogenic, anti-inflammatory and anti-proliferative activities through inhibition of both isoenzymes 5α- reductase and inhibition of binding of dihydrotestosterone (DHT) to the cytosolic androgen receptors. This is a similar mechanism exhibited by finasteride and Tamsulosin both antiprostatic conventional drugs though the plant phytochemicals do not interfere with PSA secretion. S. serrulata has also been reported to be non-toxic in both non clinical and clinical trial studies. The medicinal plants reported by this review to be used in combination include; stinging nettle (Urtica dioca), Zingiber officinalis, Echinacea angustifolia and pumpkin (Cucurbita pepo). The antiprostatic conventional drugs reported include finasteride and Tamsulosin. Conclusion and Recommendation: The results showed that S. serrulata is effective in treating prostatic diseases. The potency and safety is improved when used in combination with Urtica dioca, Cucurbita pepo, Zingiber officinalis and Echinacea angustifolia as compared with anti-prostatic conventional drugs Finasteride and Tamsulosin alone. The plant combination has also been shown to have improvement in the quality of life and as well enhancing the synergy of Finasteride and Tamsulon and their adverse effects. Effective medicinal plant combinations should be formulated into products and integrated into the usual treatment for prostatic diseases.

Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases

Urology ◽  
2004 ◽  
Vol 64 (4) ◽  
pp. 707-711 ◽  
Author(s):  
Clemens BrÖssner ◽  
Karin Petritsch ◽  
Klaus Fink ◽  
Marco Auprich ◽  
Stephan Madersbacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Tissue Levels ◽  
Prostatic Diseases

Risk of colorectal cancer subsite in a prostate cancer cohort.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 404-404
Author(s):  
Yunxia Lu ◽  
Rickard Ljung ◽  
Mats Lindblad ◽  
Jesper Lagergren
Keyword(s):  
Prostate Cancer ◽  
Colorectal Cancer ◽  
General Population ◽  
Colorectal Adenocarcinoma ◽  
Age Groups ◽  
Distal Colon ◽  
Proximal Colon ◽  
Exposed Group ◽  
Increased Risk ◽  
Almost All

404 Background: Epidemiological studies imply an association between sex hormonal related factors and the risk of colorectal cancer. Methods: A prostate cancer cohort was initiated from the Swedish Cancer Register among patients diagnosed during 1961-2008. The prostate cancer patients were followed up until a diagnosis of colorectal adenocarcinoma, death, emigration or end of study (December, 31, 2008). The cohort was stratified into a group as “estrogen exposed” who were diagnosed with prostate cancer before 1980, and a group as “estrogen less exposed” who were diagnosed after 1980. The reason for this grouping was estrogen therapy was the predominant treatment strategy in Sweden before 1980 while other treatment became more common after 1980. Standardized incidence ratios (SIRs) and 95% confidence interval (CI) were estimated as the measure of relative risk compared to the general population of the corresponding age and calendar year. SIRs were estimated for total colorectal cancer and for cancer of the proximal colon, distal colon, and rectum separately. Results: Among a total of 190,485 of prostate cancer patients contributing 708,019 person-years at risk, we identified 1493 colorectal adenocarcinoma. For those diagnosed with prostate cancer before 1980 (estrogen exposed group),almost all age groups showed a decreased risk of colorectal cancer, except for cancer of the distal colon, compared to the general population. Increased risk of colorectal cancer was instead found in almost all age groups for those diagnosed after 1980 (estrogen less exposed group). SIRs of adenocarcinoma in the proximal colon and distal colon showed different patterns. After 1980, the SIR of adenocarcinoma in the distal colon among patients followed up for >10 years was 1.29, (95% CI 1.02-1.60). Conclusions: This study indicates that exposure to estrogens protect against colorectal cancer, while treatment after 1980 displayed a potential increased risk of colorectal adenocarcinoma, especially in the distal colon.

scholarly journals Metabolic syndrome and diabetes for the urologist

2014 ◽  
Vol 8 (7-8) ◽  
pp. 159 ◽  
Author(s):  
Neil E. Fleshner ◽  
Bimal Bhindi
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Benign Prostatic Hyperplasia ◽  
Clinical Data ◽  
Prostatic Hyperplasia ◽  
Prostatic Diseases ◽  
Viable Treatment

Type 2 diabetes has a number of know urological consequences. Epidemiologic and clinical data suggest a link between metabolic syndrome and prostatic diseases such as benign prostatic hyperplasia (BPH) and prostate cancer. Recent studies have identified metformin as a viable treatment for patients with type 2 diabetes and prostate cancer.

scholarly journals An introduction to genetic and epigenetic changes in prostate gland – implications in efficacy of phytotherapy of benign prostatic hyperplasia and prostate cancer

2015 ◽  
Vol 84 (2) ◽  
pp. 97-103
Author(s):  
Joanna Bartkowiak-Wieczorek ◽  
Radosław Kujawski ◽  
Anna Bogacz ◽  
Marcin Ożarowski
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Molecular Mechanisms ◽  
Prostate Gland ◽  
Genetic Alterations ◽  
Epigenetic Modifications ◽  
Prostatic Hyperplasia ◽  
Epigenetic Changes ◽  
Prostate Diseases ◽  
Pharmacologically Active

The usage of classical pharmacological treatment of prostate diseases causes the risk of a number of side effects therefore the researchers are looking for new pharmacologically active molecules, including those contained in the plant extracts. The most widely studied is the lipido-sterolic extract from Serenoa repens (saw palmetto), water extract from Camellia sinensis (green tea) and several cruciferous vegetables. The molecular mechanisms underlying of the development and the progression of prostate disorders, especially benign prostatic hyperplasia (BPH) and prostate cancer (PC), remain still poorly understood. The development of pathologically changed prostate cells proliferation involves many factors, including genetic alterations, such as mutations, and epigenetic changes, appear to contribute to the transformation and progression of prostate cancer. In this paper we suggest that the knowledge of epigenetic modifications presented in this paper introduces the new point of view concerning the possibility of action of plant substances used in prevention and symptomatic treatment of BPH and prostate cancer. Thus, identification of the epigenetic modifications involved on the one hand in the development and progression of BPH / PC, on the other influencing the efficacy and safety of potential phytotherapeutics will be helpful in identifying its novel therapeutic strategy.

Prostate cancer incidence in a large cohort of Peruvian men affiliated to a prepaid system.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12566-e12566
Author(s):  
Alfredo Aguilar ◽  
Jorge Iberico ◽  
Silvia P Neciosup ◽  
Claudio J. Flores ◽  
Priscila I. Valdiviezo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
At Risk ◽  
General Population ◽  
Incidence Rate ◽  
Age Groups ◽  
Cumulative Risk ◽  
Incidence Rates ◽  
Specific Rate ◽  
Age Group ◽  
Assessment Period

e12566 Background: Prostate cancer (PC) is the most common malignancy and the leading cause of death by cancer in Peruvian men (age-standardized rate [ASR] of 37 new cases/100,000 men estimated by GLOBOCAN 2008). The purpose of this study was to assess the incidence of PC in a cohort of men at Oncosalud, an oncologic pre-paid system that currently has 600,000 affiliates. Methods: We evaluated a dynamic cohort (period 1989 to 2011) of men affiliated to Oncosalud – Auna, an oncologic prepaid system.The crude incidence rate per year (number of new cases/men at risk), the specific rate according to age (number of new cases / persons-year), and cumulative risk were calculated. Results: Overall, during the assessment period, the PC incidence rate per year was 183.7 and the ASR incidence was 145 per 100,000 affiliates respectively. In our cohort of affiliates there were no PC cases before 1995 (with 3061 men at risk for that year). The highest incidence rate was 160.5 registered in 1999 (12,461men at risk). Incidence rates showed a decreasing tendency since 2008 (159.7 with a population at risk of 86,408 men), reaching its lowest value in 2011(92.3 with 213,531men at risk). According to age-groups, there were no PC cases under 35 years old except for the 20-24 year old group (incidence rate 2.3). Specific incidence rates per age-group increases from the 40 year old-group (38.5). The peak of PC incidence was between 75 to 79 years old (1506.05). In the same way, the cumulative risk increases after 40 years old. Conclusions: In our cohort of affiliates, the incidence of PC is greater than the general population, it could be due to the process of negative selection; on the other hand, specific incidence rates per age-group and cumulative risk are increased after 40 years, as seen in the general population.

Sign in / Sign up

Export Citation Format

Share Document